Funded Project Details - FY2021
|Title:|| Role of mLST8 in mTORC2-dependent lung cancer that are refractory to targeted therapies|
|Congressional District Code:
||Biomedical Laboratory R&D
|| April 2018 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
Project Summary/Abstract Lung cancer is the leading cause of cancer-related deaths in the US and disproportionally affects Veterans. Lung cancer subtypes that are currently refractory to targeted therapies include tumors carrying activated K-Ras or drug-resistant EGFR mutations, as well as tumors whose genetic alterations are “unknown”. Among the “unknown” category, Rictor (a unique component of mTORC2) amplification was recently identified as a driver genetic alteration in 11-13% of non-small c...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.